Federal investigators have kicked off a probe into whether certain services drugmakers offer to doctors and patients are nothing more than thinly veiled kickbacks aimed at increasing sales, a report on Friday reveals. The services, which can include payments to patients to defray copay fees and disease education, have already sparked whistleblower lawsuits and a...